More than 783 million people around the world will suffer from diabetes by 2045, up 46% from 2021 levels. There is a need for a new and better approach to tackle diabetes.
With an innovative new product that has the potential to lead to diabetes remission, top Hua Medicine executives led by CEO Dr Li Chen are attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco from January 8-11, 2024.
Just weeks ago, Hua Medicine announced the filing of an Innovative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to launch a trial for the second generation of its global first-in-class glucokinase activator HuaTangNing (dorzagliatin tablets). Dorzagliatin has the potential to restore blood glucose control and induce remission in Type 2 diabetes patients, as shown by data from clinical studies.
Hua Medicine is a leading biotechnology company based in Shanghai and listed in Hong Kong (HKEx: 2552) focused on developing innovative treatments for diabetes and other diseases.
Hua Medicine has made significant strides over the past 15 months: received regulatory approval for dorzagliatin in mainland China, a milestone payment of RMB800 million (USD113 million) from distribution partner Bayer, seeing the inclusion of dorzagliatin in China’s National Reimbursement Drug List, and filing the an Investigational New Drug for the second-generation of dorzagliatin in the U.S.
We’d like to offer you a unique opportunity to interview Hua Medicine’s CEO Dr. Li Chen to discuss the how dorzagliatin could radically alter global efforts to fight the diabetes epidemic, the development of this innovative drug and Hua Medicine’s growth prospects in China, the U.S. and other markets.
